3Q 2026
Investor Presentation



November 2026

SBC Medical Group Holdings Incorporated

Disclaimer

This presentation contains forward-looking statements. Forward-looking statements are not historical facts or statements of current conditions, but instead represent only the beliefs of SBC Medical Group Holdings Incorporated (the "Company") regarding future events and performance, many of which, by their nature, are inherently uncertain and outside of the Company's control. These forward-looking statements reflect the Company's current views with respect to, among other things, the Company's product launch plans and strategies; growth in revenue and earnings; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," "targets" or "hopes" or the negative of these or similar terms. The Company cautions readers not to place undue reliance upon any forward-looking statements, which are current only as of the date of this presentation and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. The forward-looking statements are based on management's current expectations and are not guarantees of future performance. The Company does not undertake or accept any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. Factors that may cause actual results to differ materially from current expectations may emerge from time to time, and it is not possible for the Company to predict all of them; such factors include, among other things, changes in global, regional, or local economic, business, competitive, market and regulatory conditions, and those listed under the heading "Risk Factors" and elsewhere in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov.

Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA margin, Interest-bearing Liabilities, Net Cash, and Adjusted D/E, in evaluating its operating results and for financial and operational decision-making purposes. The Company believes that the non-GAAP financial measures help identify underlying trends in its business, provide useful information about the Company's results of operations, enhance the overall understanding of the Company's past performance and future prospects, and allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not defined under U.S. GAAP and are not presented in accordance with U.S. GAAP. The presentations of these measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. For more information on the non-GAAP financial measures, please see the table captioned "Reconciliation Table on Non-GAAP Financials" on the slide titled "Non-GAAP Financial Measures."

Table of Contents

I.	3Q 2026 Clinic Highlights	P4
II.	3Q 2026 Performance Highlights	P6
III.	Business Strategies Update	P9
IV.	Capital & IR	P15
Appendix.		P17

Ⅰ. 3Q 2026 Clinic Highlights

3Q 2026 Clinic Highlights

- Same-clinic revenue[5] grew 7% YoY, driven by growth in both customer visits and average spend per visit, alongside continued clinic network expansion

Number of Locations[1]
(as of Sep 30, 2026, YoY)

293

+36 Locations / +14%

Total Clinic Revenue[1 2 3 4]
(YTD - YoY)

$890MM +11%

Same-Clinic Revenue[5]: $836MM +7%

Average Spend per Visit[1 2 3 6 7 8]
(3Q - YoY)

$290

+4%

Number of Visits / Unique Customers[1 8 9]
(LTM - YoY)

7.06MM **+9%**

2.26MM **+10%**

Transaction Value Mix[1 2 3 6]
(YTD)



Repeat Rate[1 7 8 9 10]

73%

1 Brands: SBC brands, Rize, Gorilla, AHH, JUN CLINIC (number of clinics also includes OrangeTwist, BLEZ)
2 FX: JPY158.5/USD, JPY123.9/SGD
3 After point/ticket discounts
4 Revenue: Recognized upon service delivery
5 Same-clinic revenue: Revenue from clinics operating as of Dec 31, 2024, and not closed since
6 Total transaction value: Aggregate amount paid by customers
7 Excludes course-package effects
8 Excludes free consultations
9 AHH unique counts & repeat rates estimated from SBC brands, Rize, Gorilla, and JUN CLINIC ratios
10 Share of customers with 2 or more visits

Ⅱ. 3Q 2026 Performance Highlights

3Q 2026 Financial Performance Highlights

Total revenues	Income from operations	Adjusted EBITDA[1]	Basic EPS[5]
$59 MM	$26 MM	$28 MM	$0.15
+35% YoY	+66% YoY	+66% YoY	+25% YoY

	Unit	3Q26	QoQ	YoY	2Q26	3Q25
Total revenues	MM US$	59	+19%	+35%	49	43
Income from operations	MM US$	26	+39%	+66%	19	16
Adjusted EBITDA[1]	MM US$	28	+37%	+66%	20	17
Adjusted EBITDA margin[2]	%	47	+6pt	+9pt	41	38
Net income attributable to SBC Medical	MM US$	16	+47%	+22%	11	13
Net income margin[3]	%	27	+5pt	(3)pt	22	30
ROE (Annualized)[4]	%	23	+6pt	(0)pt	16	23
Basic EPS[5]	US$	0.15	+50%	+25%	0.10	0.12

1 Adjusted EBITDA = Net income attributable to SBC Medical + Taxes, non-operating items, and D&A (Non-GAAP Financials: see p.23)

2 Adjusted EBITDA margin (%) = Adjusted EBITDA / Total revenues (Non-GAAP Financials: see p.23)

3 Net income margin = Net income attributable to SBC Medical / Total revenues

4 ROE = Net income attributable to SBC Medical / Average of SBC Medical Group Holdings Incorporated's stockholders' equity (beginning and end of the period)

5 Basic EPS = Net income attributable to SBC Medical / Weighted average shares outstanding

3Q 2026 Performance Highlights

- Total revenues +35% YoY and income from operations +66%; operating margin improved from 37% to 45%, driven mainly by growth in management services revenue

(MM US$)	3Q26	QoQ	YoY	2Q26	3Q25
Total revenues	**59**	**+19%**	**+35%**	**49**	**43**
SBC core segment	**53**	**+19%**	**+22%**	**45**	**43**
• Franchising revenue	**10**	**+1%**	**(4)%**	**10**	**10**
• Procurement revenue	**14**	**+6%**	**+6%**	**13**	**13**
• Management services revenue	**16**	**+28%**	**+73%**	**13**	**9**
• Rental services revenue	**8**	**+108%**	**+30%**	**4**	**6**
• Other revenues	**5**	**(4)%**	**+11%**	**5**	**4**
Waqoo segment	**6**	**+23%**	**NM**	**5**	**—**
Cost of revenues	**16**	**+24%**	**+29%**	**13**	**13**
Gross profit	**42**	**+17%**	**+38%**	**36**	**31**
Operating expenses	**16**	**(7)%**	**+7%**	**17**	**15**
Income from operations	**26**	**+39%**	**+66%**	**19**	**16**
Net income attributable to SBC Medical	**16**	**+47%**	**+22%**	**11**	**13**

Change & Contributing Factors - YoY (MM US$)

Total revenues: +15.2 (FX impact: (4.2))

(Figures below exclude FX impact)

- **Management services revenue: +8.2**
  Revision of certain service fee structures announced in August, and reduction in promotional expenses for the points business
- **Rental services revenue: +2.5**
  Medical equipment installed for newly opened clinics
- **Waqoo consolidation: +5.6**
  Revenue contribution from the newly consolidated segment

Net income attributable to SBC Medical: +2.9 (FX impact: (1.4))

Core profit growth was partially offset by FX, higher taxes, and equity-method losses

1 FX Impact = Current actuals − Value at PY rates

2 FX: SBC (3Q26 JPY159.1/USD, 2Q26 JPY159.3/USD, 3Q25 JPY147.4/USD), Waqoo (3Q26 JPY159.2/USD, 2Q26 JPY156.9/USD)

Ⅲ. Business Strategies Update

Roadmap for the Full-Scale Rollout of Our Longevity Business

- Leveraging our extensive clinic network as a source of competitive advantage, we will build an end-to-end platform — from testing and diagnostics to personalized treatment and verification of outcomes — in stages through 2028

Today

Broad Customer Touchpoints

- 293 locations staffed by physicians and nurses
  - Appearance: aesthetics and anti-aging
  - Physical Function: AGA, dentistry, orthopedics, ophthalmology, fertility treatment & gynecology
  - Regenerative medicine (CellPro)

November 2026

Diagnostics — Step 1

- Initiation of development for in-house blood biomarker testing (Waqoo)
  - Offering the test throughout the clinic network
  - Recurring testing = recurring revenue and data

2027

Longevity Center + Online

- Establish a Longevity Center
- Online platform: coaching and tracking
- Epigenetic age buccal swab test (spring 2027)

2027–28

AI × Physicians, Global

- AI-generated protocols reviewed by physicians
  - Closing the loop: Diagnose → Personalize → Intervene → Re-measure
- Rolling out the Longevity menu to the US (OrangeTwist) and Southeast Asia

SBC already owns the hardest piece to build — the treatment-delivery infrastructure

■ **By combining diagnostics and AI with the treatment-delivery infrastructure we already own, we expect to establish a distinctive competitive advantage in the Longevity market**

Development of DNA Methylation Testing — Measuring Biological Age

- We have begun in-house development of DNA methylation testing to estimate biological age, drawing on the research and technology base Waqoo Group has built in regenerative medicine

Why DNA Methylation

- Unlike genes, methylation can change with lifestyle and environment
- A promising measure for tracking the effect of lifestyle changes over time
- Research has advanced since 2013[1]; in 2025, a method was shown to estimate the age of 11 organs and systems from a single blood draw[2]

Three Pillars of Development

1. Organ-Level Mapping

Assess biological age by organ and system

2. Non-Invasive Measurement

Research measurement methods that require no blood draw

3. Japan-Specific Data

Leveraging data unique to Japan, the world’s oldest society

■ **Through in-house development of DNA methylation testing, we aim to make biological age and treatment outcomes visible and to deliver data-driven, personalized care**

1 Horvath S., Genome Biology (2013)　2 Sehgal R. et al., Nature Aging (2025)

Building Our Own Local LLM — Secure AI Strategy to Utilize Medical Data

- We are building our own local LLM foundation that protects medical data and enables AI features built on our proprietary data

Why Local LLM

- Builds on SBC's proprietary clinical and customer data to deliver features that general-purpose AI cannot easily replicate
- Decouples inference costs from cloud API pricing, improving economics

Six AI Features Being Developed with Our Proprietary Local LLM

Voice-to-EMR Automation — Cost

AI speech recognition drafts a chart in about one second — giving physicians and nurses time back for patients

Shift Scheduling — Cost

Optimizes staffing across 293 locations — cutting scheduling effort, idle time and overtime

Security Monitoring — Risk

AI monitoring of clinical systems and data access

Clinic Marketing Planner — Revenue

Generates promotional creative assets — lowering ad spend per booking

Treatment Plan for Clinics — Revenue

Suggests the best next treatment from 26 years of case data — lifting spend per visit

Personal Recommendations for Customers — Revenue

Recommendations based on each customer's treatment history — raising LTV

■ Our own local LLM foundation enables the secure use of medical data and optimized AI costs, accelerating productivity and revenue growth through the development and rollout of proprietary AI features

Advancing Our Clinic Platform — Co-Development with Atomic Software

- Capital & business alliance with Atomic Software, provider of Japan's leading self-pay clinic platform "medicalforce," to co-develop new features that boost clinics' productivity and profitability

Why Atomic Software

Unmatched Adoption and Retention

- Adopted by more than 800 clinics in Japan as core SaaS for cash-pay care[1]
- A 99.2%[2] retention rate

An integrated system purpose-built for cash-pay care

- Booking, EMR, payments, customer management, and analytics in one system
- Supports cash-pay specifics such as linked room/equipment/staff booking and service and case-photo management

A proven track record at clinics we support

- Already in production as the core and payment system at Hada no Aozora Clinic
- That on-the-ground track record was decisive for this alliance

Three Steps to Value Creation

1. Co-Develop AI Features

The two companies will develop features that support physicians' clinical documentation

2. Implement in Our Own Systems

Validate at the clinics we support and roll the results into our clinic operating systems

3. Extend to New Brands and Formats

Standardize the rollout to shorten opening lead times and stabilize operations sooner

■ Streamlining clinic operations lifts profitability at existing clinics and speeds up new openings

1 Number of clinics as of September 2026 (per Atomic Software) 2 Retention rate as of March 2026 (Atomic Software research)

Selected for Newsweek's World Medical Tourism Ranking 2027

- Shonan Beauty Clinic selected in two plastic surgery categories (top 75 in each)[1]
- 3Q26 number of overseas customers' visits[2] grew +86% YoY

Survey Overview


- **Name:**
  World's Best Hospitals & Clinics for Medical Tourism 2027
- **Published by:**
  Newsweek (research by Statista)
- **Publication date:**
  November 3, 2026 (US time)



- **Review period:** September 3, 2025 – September 2, 2026
- **Coverage:** 13 countries
- **Categories:** Plastic Surgery
  — Liposuction and Breast Augmentation
  (Top 75 facilities selected in each category)
- **Listed as:** Shonan Beauty Clinic (Shinjuku, Japan)

Our Results and Initiatives for Overseas Customers

Number of Overseas Customers' visits (3 months)



YoY +86%
3Q26 vs. 3Q25

Trust within the medical community

- In 2025, 75 physicians at SBC-supported clinics presented research at 28 medical conferences in Japan and abroad

Support Framework

- Released AI interpretation app "Talk Bridge"
- Established a CN/EN interpretation center & "Global Beauty Advisors"

■ **International recognition lifts our brand overseas and accelerates our growing inbound business**

1 Newsweek / Statista, World's Best Hospitals & Clinics for Medical Tourism 2027
2 SBC brands (excluding Rize, Gorilla, AHH, JUN CLINIC, and BLEZ)

Ⅳ. Capital & IR

Capital & IR — Improving Share Liquidity

- Average daily trading value[1] [2] of SBC shares reached $1,026K in October, with share liquidity steadily improving
- We will continue active investor engagement to further raise SBC’s recognition in the equity market

Average daily trading value[1] [2]


4.1x (vs Jul. 2026)

Oct. 2026: approx. $1,026K
Jul. 2026 : approx. $ 253K

Beneficial Shareholders [3]

1.6x (vs Jul. 2026)

As of the end of
Oct. 2026: approx. 7,300 accounts
Jul. 2026 : approx. 4,400 accounts



IR Activities (Jan–Oct 2026)

183

1-on-1 investor meetings

22

IR conferences attended

■ **By broadening our investor base, we aim to improve share liquidity and achieve a share price that properly reflects our medium- to long-term corporate value**

1 Average daily trading value = Σ (daily volume × closing price) / number of trading days
2 July: Jul 6 – Jul 31; October: Oct 5 – Oct 30 (20 trading days each)
3 Beneficial accounts (positions) based on Broadridge data as of the record dates (Jul 11, 2025; Jul 31, 2026; Oct 30, 2026)

Appendix.

9M 2026 Performance Highlights

(MM US$)	9M26	YoY	9M25
Total revenues	**151**	**+13%**	**134**
SBC core segment	**141**	**+5%**	**134**
• Franchising revenue	**28**	**(21)%**	**36**
• Procurement revenue	**40**	**(8)%**	**43**
• Management services revenue	**41**	**+76%**	**23**
• Rental services revenue	**15**	**(18)%**	**19**
• Other revenues	**16**	**+25%**	**13**
Waqoo segment	**10**	**NM**	**—**
Cost of revenues	**42**	**+19%**	**36**
Gross profit	**109**	**+10%**	**98**
Operating expenses	**45**	**+4%**	**44**
Income from operations	**63**	**+15%**	**55**
Net income attributable to SBC Medical	**38**	**+2%**	**37**

Change & Contributing Factors - YoY (MM US$)

Total revenues: +16.8 (FX impact: (9.9))

(Figures below exclude FX impact)

- **Franchising revenue: (5.5)**

  Impact of the revision to the consulting fee structure in April 2025

- **Management services revenue: +20.7**

  Reduction in promotional expenses for the points business, and revision of certain service fee structures announced in August

- **Rental services revenue: (2.3)**

  Reactionary decline from the large-scale equipment replacement in 2025

- **Other revenues: +4.4**

  Growth at AHH and leasehold improvement services

- **Waqoo consolidation: +10.0**
  Revenue contribution from the newly consolidated segment

Net income attributable to SBC Medical: +0.9 (FX impact: (2.9))

Gain on redemption of life insurance policies in the PY

1 FX Impact = Current actuals − Value at PY rates

2 FX: SBC (9M26 JPY158.5/USD, 9M25 JPY148.1/USD), Waqoo (2-3Q26 JPY158.2/USD)

Consolidated Income Statement

(MM US$)	3Q26	QoQ	YoY	2Q26	3Q25	9M26	YoY	9M25
Total revenues	59	+19%	+35%	49	43	151	+13%	134
SBC core segment	53	+19%	+22%	45	43	141	+5%	134
• Franchising revenue	10	+1%	(4)%	10	10	28	(21)%	36
• Procurement revenue	14	+6%	+6%	13	13	40	(8)%	43
• Management services revenue	16	+28%	+73%	13	9	41	+76%	23
• Rental services revenue	8	+108%	+30%	4	6	15	(18)%	19
• Other revenues	5	(4)%	+11%	5	4	16	+25%	13
Waqoo segment	6	+23%	NM	5	—	10	NM	—
Cost of revenues	16	+24%	+29%	13	13	42	+19%	36
Gross profit	42	+17%	+38%	36	31	109	+10%	98
Operating expenses	16	(7)%	+7%	17	15	45	+4%	44
• Salaries and welfare	7	(5)%	+12%	8	7	21	+8%	20
• Depreciation and amortization	0	+1%	(51)%	0	1	1	(39)%	2
• Consulting and professional services	3	(36)%	(25)%	5	4	12	+3%	12
• Office, utility, and other expenses	2	+16%	+20%	2	2	5	(3)%	5
• Other	2	+35%	+118%	2	1	6	+11%	5
Income from operations	26	+39%	+66%	19	16	63	+15%	55
Net income attributable to SBC Medical	16	+47%	+22%	11	13	38	+2%	37

Consolidated Balance Sheet

(MM US$)	Sep. 2026	Change	Dec. 2025
TOTAL ASSETS	425	+44	380
Total current assets	274	+43	231
• Cash and cash equivalents	198	+35	164
• Accounts receivable – related parties	31	+3	28
• Customer loans receivable, current	4	(5)	9
• Other assets	41	+9	31
Total non-current assets	151	+2	149
• Property and equipment, net	9	+1	8
• Intangible assets, net	45	(3)	48
• Operating lease right-of-use assets	10	+2	8
• Finance lease right-of-use assets	0	(0)	0
• Customer loans receivable, non-current	2	(2)	5
• Long-term investments in MCs – related parties	18	(0)	18
• Other assets	67	+4	62

(MM US$)	Sep. 2026	Change	Dec. 2025
TOTAL LIABILITIES	121	+4	117
Total current liabilities	75	+14	61
• Accounts payable	23	+6	17
• Bank and other borrowings, current	9	(0)	9
• Advances from customers – related parties	4	(2)	5
• Income tax payable	17	+8	9
• Operating lease liabilities, current	6	+1	4
• Finance lease liabilities, current	0	(0)	0
• Other liabilities	16	+0	16
Total non-current liabilities	47	(9)	56
• Bank and other borrowings, non-current	25	(9)	34
• Operating lease liabilities, non-current	5	+0	4
• Finance lease liabilities, non-current	0	(0)	0
• Other liabilities	17	(1)	18
Total stockholders' equity	303	+40	263
SBC Medical Group Holdings Incorporated stockholders' equity	287	+39	248
Non-controlling interests	17	+2	15

Consolidated Statement of Cash Flows

(MM US$)	9M26	YoY	9M25
Net cash provided by (used in) operating activities	50	+77	(27)
Net cash provided by (used in) investing activities	(5)	(8)	3
Net cash provided by (used in) financing activities	(9)	(27)	18
Effect of changes in foreign currency exchange rate	(2)	(10)	8
Net change in cash and cash equivalents	35	+32	2
Cash and cash equivalents at the beginning of the period	164	+39	125
Cash and cash equivalents at the end of the period	198	+71	127

Strong Financial Foundation for Growth

- Strong financial base ($154M net cash, 68% equity ratio) to support continued growth investments

Cash and Cash Equivalents	Interest-Bearing Liabilities[2]	Net Cash[4]
$198 MM	$44 MM	$154 MM Net cash per share[5] : $1.51
Capital Ratio[1]	**Adjusted D/E[3]**	**BPS[6]**
68%	0.15x	$2.80

1 Capital Ratio = SBC Medical Group Holdings Incorporated Stockholders' Equity / Total Assets
2 Includes operating lease obligations (Non-GAAP Financials: see p.24)
3 Adjusted D/E = Interest-bearing Liabilities / Total Stockholders' Equity (Non-GAAP Financials: see p.24)
4 Net Cash = Cash and Cash Equivalents − Interest-bearing Liabilities (Non-GAAP Financials: see p.24)
5 Net Cash per share = Net Cash / Shares Outstanding
6 BPS = SBC Medical Group Holdings Incorporated Stockholders' Equity / Shares Outstanding
7 Figures for major consolidated balance sheet items shown on this slide: see p.20
Full balance sheet in our related earnings release, dated November 13, 2026

Non-GAAP Financial Measures

This presentation references certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are shown below.

Reconciliation Table on Non-GAAP Financials

(MM US$)		3Q26	2Q26	3Q25
(A)	Total revenues	59	49	43
(B)	Net income attributable to SBC Medical	16	11	13
(C)	Net income attributable to non-controlling interests	1	0	0
(D)	Equity in losses of equity method investees, net of tax	1	1	—
(E)	Income tax expense	9	8	6
(F)	Gain on redemption of life insurance policies	—	—	—
(G)	Other expenses	—	0	0
(H)	Other income	(1)	(0)	(2)
(I)	Foreign currency exchange loss (gain), net	1	(1)	(1)
(J)	Interest expense	0	0	0
(K)	Interest income	(0)	(0)	(0)
(L)	Depreciation and amortization expense	1	1	1
(M) = (B)+(C)+…+(L)	**Adjusted EBITDA**	**28**	**20**	**17**
(N) = (B) / (A)	**Net income margin**	**27%**	**22%**	**30%**
(O) = (M) / (A)	**Adjusted EBITDA margin**	**47%**	**41%**	**38%**

Non-GAAP Financial Measures

This presentation references certain non-GAAP financial measures. Reconciliations of such measures to the most directly comparable GAAP measures are shown below.

Reconciliation Table on Non-GAAP Financials

(MM US$)			Sep. 2026	Dec. 2025
(A)		Bank and other borrowings, current	9	9
(B)		Bank and other borrowings, non-current	25	34
(C)		Operating lease liabilities, current	6	4
(D)		Operating lease liabilities, non-current	5	4
(E)		Finance lease liabilities, current	0	0
(F)		Finance lease liabilities, non-current	0	0
(G)	= (A)+(B)+…+(F)	**Interest-Bearing Liabilities**	**44**	**52**
(H)		Cash and cash equivalents	198	164
(I)	= (H) – (G)	**Net Cash**	**154**	**112**
(J)		Total stockholders' equity	303	263
(K)	= (G) / (J)	**Adjusted D/E**	**0.15x**	**0.20x**

Investment Highlights

1	**Japan's #1[1] aesthetic healthcare platform**	A highly profitable Medical Services Organization (MSO) model with 7.06MM annual visits, a 73% repeat rate[2], and a 47% adjusted EBITDA margin[2] [3]
2	**Longevity: we already own the hardest piece to build — the platform that delivers treatment**	Combining diagnostics and AI with our existing medical infrastructure to build an end-to-end Longevity platform
3	**Two-way global expansion**	Importing Longevity know-how from the US and taking Japan's clinic operating model to the US and Asia
4	**AI turns 26 years of data into earnings growth**	Using accumulated clinical and customer data with AI to drive revenue growth and greater operating leverage
5	**Physical medical infrastructure — increasingly scarce in the age of AI**	The ability to deliver care through licensed clinics and physicians cannot easily be replicated
6	**A highly profitable compounding model backed by a strong financial base**	Net cash of $154 MM[4]. Pursuing growth investment funded by operating cash flow and sustained EPS growth

1 Yano Research Institute, "Outlook and Strategy for Cosmetic Medicine 2026" (by number of clinics and total clinic revenue)

2 3Q26 figures

3 Adjusted EBITDA margin (%) = Adjusted EBITDA / Total revenues (Non-GAAP Financials: see p.23)

4 Net Cash = Cash and Cash Equivalents − Interest-bearing Liabilities (Non-GAAP Financials: see p.24)

SBC Medical Group Holdings Incorporated

Thank you

Contact: ir@sbc-holdings.com

IR Site

LinkedIn